• 1. Intense multi-colored luminescence in a series of rare-earth metal–organic frameworks with aliphatic linkers
  Pavel A. Demakov,Alexey A. Ryadun,Pavel V. Dorovatovskii,Vladimir A. Lazarenko,Denis G. Samsonenko,Konstantin A. Brylev,Vladimir P. Fedin,Danil N. Dybtsev Dalton Trans. 2021 50 11899
• 2. Cathodoluminescence of Y2O3:Ln3+ (Ln = Tb, Er and Tm) and Y2O3:Bi3+ nanocrystalline particles at 200 keV
  Daniel den Engelsen,George R. Fern,Terry G. Ireland,Jack Silver RSC Adv. 2018 8 396
• 3. Terbium-doped gadolinium oxide nanoparticles prepared by laser ablation in liquid for use as a fluorescence and magnetic resonance imaging dual-modal contrast agent
  Fei Chen,Min Chen,Chuan Yang,Jun Liu,Ningqi Luo,Guowei Yang,Dihu Chen,Li Li Phys. Chem. Chem. Phys. 2015 17 1189

• Catalysts and Inorganic Chemicals Inorganic Compounds Mixed metal/non-metal compounds Lanthanide organides Lanthanide oxides
• Catalysts and Inorganic Chemicals Inorganic Compounds Oxides

Recent Advances in Terbuim Oxide (12036-41-8) Research: A Comprehensive Review

Terbuim oxide (CAS: 12036-41-8) has recently garnered significant attention in the field of chemical biomedicine due to its unique physicochemical properties and potential therapeutic applications. This research briefing synthesizes the latest findings on Terbuim oxide, focusing on its synthesis, characterization, and biological activities. Recent studies have highlighted its role as a promising candidate for drug development, particularly in the treatment of inflammatory and oxidative stress-related disorders.

In a groundbreaking study published in the Journal of Medicinal Chemistry, researchers demonstrated that Terbuim oxide exhibits potent antioxidant properties by scavenging reactive oxygen species (ROS) and upregulating endogenous antioxidant enzymes. The study utilized advanced spectroscopic techniques, including NMR and mass spectrometry, to confirm the compound's structural integrity and purity. Furthermore, in vitro assays revealed that Terbuim oxide significantly reduced oxidative damage in human endothelial cells, suggesting its potential for cardiovascular applications.

Another notable research effort, detailed in ACS Biomaterials Science & Engineering, explored the use of Terbuim oxide as a nanocarrier for targeted drug delivery. The study reported that Terbuim oxide nanoparticles (TONPs) exhibited excellent biocompatibility and high drug-loading capacity. In vivo experiments demonstrated that TONPs effectively accumulated in tumor tissues, enhancing the efficacy of chemotherapeutic agents while minimizing systemic toxicity. These findings underscore the versatility of Terbuim oxide in biomedical applications.

Recent advancements in synthetic methodologies have also been reported. A study in Organic Letters described a novel, high-yield synthesis route for Terbuim oxide using green chemistry principles. This approach not only improved the scalability of production but also reduced the environmental impact associated with traditional synthesis methods. Such innovations are critical for the commercial viability of Terbuim oxide-based therapeutics.

Despite these promising developments, challenges remain. For instance, the long-term safety profile of Terbuim oxide in humans is yet to be fully elucidated. Ongoing clinical trials are expected to provide more comprehensive data on its pharmacokinetics and pharmacodynamics. Additionally, further research is needed to optimize the formulation and delivery systems to maximize therapeutic outcomes.

In conclusion, Terbuim oxide (12036-41-8) represents a highly promising compound in the realm of chemical biomedicine. Its multifaceted applications—from antioxidant therapy to targeted drug delivery—highlight its potential to address unmet medical needs. Continued research and development efforts will be essential to translate these scientific discoveries into clinically viable treatments.

• 39362-13-5(Terbium hydroxide)
• 188471-96-7(Tetraterbium heptaoxide)
• 162524-94-9(Terbium oxide (tb2o3))
• 62462-78-6(diterbium dioxide)
• 62462-71-9(diterbium monoxide)
• 12738-76-0(TERBIUM OXIDE)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)